Loading...
•
Jun 30, 2021
SpringWorks Therapeutics Q2 2021 Earnings Report
Reported financial results for the second quarter and year-to-date periods ended June 30, 2021, and provided an update on recent company developments.
Key Takeaways
SpringWorks Therapeutics executed well in Q2 2021, advancing the nirogacestat strategy, extending mirdametinib patent protection, and expanding the oncology pipeline.
Entered into a clinical collaboration with Seagen to evaluate Nirogacestat in combination with SEA-BCMA.
Announced the issuance of a new U.S. composition of matter patent to a polymorphic form of Mirdametinib, extending patent protection into 2041.
Announced several new clinical trials for Mirdametinib, including a Phase 1/2 trial in children and young adults with low-grade glioma and a Phase 1b/2a trial in patients with advanced solid cancers harboring selected MAPK-activating mutations.
Expanded the targeted oncology pipeline with an exclusive worldwide license to the TEA Domain (TEAD) Inhibitor Portfolio.
SpringWorks Therapeutics
SpringWorks Therapeutics
Forward Guidance
The company expects important data readouts across its late-stage rare oncology, BCMA combinations in multiple myeloma and metastatic solid tumor programs, including topline data from the Phase 3 DeFi study, and will continue to advance its 15 development programs.